MMP23B and endometrial cancer: We found that patients with low expression of MMP23B (Matrix Metalloproteinase 23B) had a higher survival rate around 7 years, and it was an independent risk factor for the survival of endometrial cancer, indicating that high expression of MMP23B (Matrix Metalloproteinase 23B) is associated with poor prognosis of endometrial cancer, and suggesting that MMP23B (Matrix Metalloproteinase 23B) may be a potential biomarker for the treatment of endometrial cancer.